OTC Markets OTCPK - Delayed Quote USD

AVITA Medical, Inc. (AVHHL)

Compare
1.8600
0.0000
(0.00%)
At close: January 15 at 3:00:00 PM EST
Loading Chart for AVHHL
DELL
  • Previous Close 0.0000
  • Open 1.8600
  • Bid 1.5200 x 306100
  • Ask 2.3200 x 381200
  • Day's Range 1.8600 - 1.8600
  • 52 Week Range 1.4100 - 3.4500
  • Volume 100
  • Avg. Volume 85
  • Market Cap (intraday) 243.824M
  • Beta (5Y Monthly) 1.54
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4500
  • Earnings Date Feb 24, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

www.avitamedical.com

207

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AVHHL

View More

Performance Overview: AVHHL

Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

AVHHL
27.34%
S&P 500
0.73%

1-Year Return

AVHHL
32.85%
S&P 500
24.38%

3-Year Return

AVHHL
13.49%
S&P 500
27.60%

5-Year Return

AVHHL
81.47%
S&P 500
81.23%

Compare To: AVHHL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AVHHL

View More

Valuation Measures

Annual
As of 1/15/2025
  • Market Cap

    233.86M

  • Enterprise Value

    235.08M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.98

  • Price/Book (mrq)

    19.94

  • Enterprise Value/Revenue

    3.92

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -95.47%

  • Return on Assets (ttm)

    -45.37%

  • Return on Equity (ttm)

    -152.44%

  • Revenue (ttm)

    60.04M

  • Net Income Avi to Common (ttm)

    -57.32M

  • Diluted EPS (ttm)

    -0.4500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    44.41M

  • Total Debt/Equity (mrq)

    373.16%

  • Levered Free Cash Flow (ttm)

    -33.68M

Research Analysis: AVHHL

View More

Company Insights: AVHHL

Research Reports: AVHHL

View More

People Also Watch